Navigation Links
Neodyne Biosciences Announces Issuance of U.S. Patent for Devices and Methods for Dressing Applicators
Date:12/3/2013

MENLO PARK, Calif., Dec. 3, 2013 /PRNewswire/ -- Neodyne Biosciences, a medical device company focused on the development and commercialization of innovative tissue repair devices to promote healing and minimize scar formation, announced today that it has been issued U.S. Patent No. 8,592,640 entitled "Devices and Methods for Dressing Applicators." 

This marks the 7th issued patent in the Neodyne Biosciences portfolio and further supports the company's first product, embrace® Advanced Scar Therapy, which received 510(k) clearance from the US Food and Drug Administration (FDA) in September, 2011. embrace® Advanced Scar Therapy delivers a unique mechanism of action to off-load tension across a newly formed scar, and has been proven to significantly improve scar appearance in a randomized, controlled study.[1]

"Adding another patent to our intellectual property portfolio strengthens our position in the marketplace as we continue to address physician and patient demand for an effective treatment of post-surgical scarring," said Bill Beasley, President of Neodyne Biosciences.

The newly issued patent is owned by Neodyne Biosciences and is accessible on the USPTO's website at www.uspto.gov.

About Neodyne Biosciences, Inc.

Neodyne Biosciences (www.neodynebio.com) is an evidence based company developing and commercializing innovative tissue repair devices to minimize scar formation, restoring both function and aesthetic appearance. The company is developing stress-shielding devices capable of controlling the mechanical wound environment to ameliorate post-surgical scarring. Although the etiology remains unclear, mechanical forces such as surrounding skin tension and body movement have been demonstrated to increase fibrosis and scar formation. It is estimated that approximately 80 million major surgical procedures are performed in the United States each year and 230 million performed worldwide. Patient frustration with post-surgical scarring spans a variety of procedures with many seeking means of prevention and treatment.

Investor Relations Contacts:

Bill Beasley

President/COO

bbeasley@neodynebio.com

Randy Haden 

Vice President, Sales

rhaden@neodynebio.com

[1] Lim AF, et al. The embrace Device Significantly Decreases Scarring Following Scar Revision Surgery in a Randomized Control Trial. (In press, Plastic and Reconstructive Surgery)


'/>"/>
SOURCE Neodyne Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ARMO BioSciences Initiates Phase 1 Clinical Trial of First-In-Class Cancer Immunotherapy
2. 3-V Biosciences Names Dr. William McCulloch Chief Medical Officer
3. Lilly Statement on Contribution to Indiana Biosciences Research Institute
4. Indiana Biosciences Research Institute Hits $50 Million Start-Up Funding Goal
5. Regado Biosciences, Inc. Adds Global Pharmaceutical Business Veteran to Board of Directors
6. Pressure BioSciences, Inc. Discusses Record Third Quarter Revenue, Strong Fourth Quarter Guidance, Significant Progress on New Instrument Systems, and Expectation to Pay-Off All Outstanding Convertible Notes at the SeeThruEquity Financial Conference
7. Regado Biosciences, Inc. Announces Third Quarter 2013 Results
8. ViGene Biosciences Introduces Worlds Largest Collection of Pre-Made Human Full-Length cDNA ORF and miRNA Adenoviruses
9. Sangamo BioSciences Presents Clinical Data From SB-728-T HIV Study Demonstrating Long-Term Immune Reconstitution and Reduction in the HIV DNA Reservoir In Subjects with Long-Term Infection
10. Ambit Biosciences to Announce Third Quarter 2013 Financial and Operating Results and Conference Call
11. Calithera Biosciences Secures $35 Million in Series D Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)... , May 9, 2017  Demonstrating its ... board of directors for the Pharmaceutical Research and ... for membership. Biopharmaceutical companies will now have to ... order to be eligible to join PhRMA. ... the board is sending a clear message that ...
(Date:5/8/2017)... 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO)., has completed ... a health care service center company based in ... in relationship management programs for leading pharmaceutical manufacturers and ... WRB will join Envoy Health Management, LLC ... manufacturers, biotech firms, and other service companies. Together, WRB ...
(Date:5/4/2017)... 4, 2017  Fortuna Fix Inc. (" Fortuna "), ... first to eliminate the need for embryonic and fetal stem ... neurodegenerative diseases. Fortuna announced today the ... Michael Fehlings , MD, PhD; Father Kevin FitzGerald , ... and Professor James Giordano , PhD. "We ...
Breaking Medicine Technology:
(Date:5/26/2017)... , ... May 26, 2017 , ... After raising nearly ... Top gadget will continue to be available at a discounted crowdfunding price on ... stress wherever they are, I also wanted to bring a fidget toy to the ...
(Date:5/26/2017)... ... May 26, 2017 , ... “When the Stars Lead Home”: a ... creation of published author Laura Weigel Douglas, an avid reader who lives in the ... that sometimes feels like Green Hills Adventure Camp. She couldn’t be more grateful. , ...
(Date:5/26/2017)... ... May 26, 2017 , ... Water damage to the flooring ... School District had left education officials with a number of critical issues to address ... flooring had to be accomplished with little or no disruption to class schedules. Second, ...
(Date:5/24/2017)... San Diego, California (PRWEB) , ... May 24, ... ... patient care through innovative medical image management and interpretation, has received U.S. Food ... technology. , Nucleus.io is a web-based, scalable and secure cloud platform for ...
(Date:5/24/2017)... ... May 24, 2017 , ... Myers Jackson is well known for auctioning homes ... luxury homes anywhere on the planet. The luxury home market is alive and well ... city-scapes. A quick search of “11 Spyglass Hill Auction will enlighten you on the ...
Breaking Medicine News(10 mins):